IL6 and acute myeloid leukemia: It has been found that intervention of AML cells with the AML chemotherapeutic drug agranulocyte (Ara-C) increases TNF-α production, which in turn activates the IL-6/STAT3 and NF-κB pathways to amplify MDSCs and enhance their immunosuppressive function [106].